BirchBioMed Inc. has announced Hamilton Health Sciences’ (HHS) Center for Burn Research as the first clinical trial site for their Phase II / III randomized study. Based in Ontario, Canada, the HHS study site will be one of up to 10 sites involved in the research evaluating the naturally based compound, Kynurenic acid (FS2). The objective is to assess FS2 cream efficacy for scar formation in patients with burn injuries that need skin graft surgery. Canfield’s Clinical Imaging Services team configured a compliant and validated solution to provide 3D surface area measurement performed with the patient on-site and high-quality photo documentation to support the subjective rating scale assessments and measure scar healing.

This next pivotal phase should begin enrolling the first patients by September 2025.

Canfield Scientific is honored to support studies aimed at improving healing and quality of life for patients world-wide. Our Clinical Services Specialists and Imaging Scientists, backed by decades of experience, are the leaders in advanced validated skin imaging technologies.

BirchBioMed Inc. is a leading biopharmaceutical company with expertise in product development for scarring, organ fibrosis, autoimmune diseases and skin disorders.

The HHS’ Centre for Burn Research specializes in the research and development of evidence-based treatment plans to enhance outcomes for burn patients.

To learn more about Canfield Scientific’s Clinical Services, click here.

To learn more about BirchBioMed Inc., click here.

To learn more about HHS’ Center for Burn Research, click here.